Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) EBITDA: 2009-2021

Historic EBITDA for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Dec 2021 value amounting to -$23.1 million.

  • Avadel Pharmaceuticals' EBITDA fell 62.24% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$85.5 million, marking a year-over-year decrease of 1571.13%. This contributed to the annual value of -$85.5 million for FY2021, which is 1571.13% down from last year.
  • According to the latest figures from Q4 2021, Avadel Pharmaceuticals' EBITDA is -$23.1 million, which was up 9.85% from -$25.7 million recorded in Q3 2021.
  • Avadel Pharmaceuticals' 5-year EBITDA high stood at $40.3 million for Q2 2020, and its period low was -$75.4 million during Q4 2018.
  • For the 3-year period, Avadel Pharmaceuticals' EBITDA averaged around -$8.7 million, with its median value being -$10.9 million (2019).
  • In the last 5 years, Avadel Pharmaceuticals' EBITDA plummeted by 1,748.55% in 2018 and then spiked by 1,004.72% in 2020.
  • Over the past 5 years, Avadel Pharmaceuticals' EBITDA (Quarterly) stood at -$4.1 million in 2017, then crashed by 1,748.55% to -$75.4 million in 2018, then skyrocketed by 90.26% to -$7.3 million in 2019, then slumped by 94.09% to -$14.3 million in 2020, then slumped by 62.24% to -$23.1 million in 2021.
  • Its EBITDA stands at -$23.1 million for Q4 2021, versus -$25.7 million for Q3 2021 and -$21.9 million for Q2 2021.